Northwest Biotherapeutics, Inc. (NWBO)
Oxford Ledge is still expanding full research coverage of NWBO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biotechnology company developing dendritic cell-based cancer immunotherapies with lead product in regulatory review and orphan drug status.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-04-15
- 8-K Completion of acquisition or disposition 2026-04-07
- 8-K Other material event 2026-01-15
- 8-K Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-01-02
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NWBO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NWBO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.